This data along with observation that GLP-1R signaling enhanced levels of serotonin, dopamine (DA), and their receptors (263, 271), has potentiated the use of GLP-1R agonists as a management strategy for mental illness and neurodegenerative diseases. This evidence concerns the gene GLP1R and neurodegenerative disease.